BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24798046)

  • 1. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation.
    Ding X; Yang Y; Han B; Du C; Xu N; Huang H; Cai T; Zhang A; Han ZG; Zhou W; Chen L
    PLoS One; 2014; 9(5):e95307. PubMed ID: 24798046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections.
    Tornesello ML; Buonaguro L; Tatangelo F; Botti G; Izzo F; Buonaguro FM
    Genomics; 2013 Aug; 102(2):74-83. PubMed ID: 23583669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of polymorphisms in the Wnt/β-catenin pathway genes on hepatocellular carcinoma risk in a Chinese Han population.
    Li QM; Zhang FQ; Li YF; Xian QJ; Zhang YQ; Li P
    Medicine (Baltimore); 2017 Mar; 96(12):e6127. PubMed ID: 28328801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.
    Vivekanandan P; Torbenson M; Ramakrishna B
    J Gastrointest Cancer; 2011 Mar; 42(1):20-5. PubMed ID: 20963515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/beta-catenin signaling pathway in hepatocellular carcinomas cases from Colombia.
    Suarez M I; Uribe D; Jaramillo CM; Osorio G; Perez JC; Lopez R; Hoyos S; Hainaut P; Pineau P; Navas MC
    Ann Hepatol; 2015; 14(1):64-74. PubMed ID: 25536643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of CTNNB1 and TP53 variability in patients with hepatocellular carcinoma and occult hepatitis B virus infection.
    Saitta C; Lanza M; Bertuccio A; Lazzara S; Navarra G; Raimondo G; Pollicino T
    Cancer Genet; 2015 Oct; 208(10):513-6. PubMed ID: 26341700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis.
    Hsu HC; Jeng YM; Mao TL; Chu JS; Lai PL; Peng SY
    Am J Pathol; 2000 Sep; 157(3):763-70. PubMed ID: 10980116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
    Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
    Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion.
    Wong AM; Ding X; Wong AM; Xu M; Zhang L; Leung HH; Chan AW; Song QX; Kwong J; Chan LK; Man M; He M; Chen J; Zhang Z; You W; Lau C; Yu A; Wei Y; Yuan Y; Lai PB; Zhao J; Man K; Yu J; Kahn M; Wong N
    J Hepatol; 2022 Aug; 77(2):410-423. PubMed ID: 35351523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
    Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
    Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
    Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous phenotypes of Pten-null hepatocellular carcinoma in hepatitis B virus transgenic mice parallels liver lobule zonal gene expression patterns.
    Oropeza CE; Ondracek CR; Tarnow G; Maienschein-Cline M; Green SJ; McLachlan A
    Virology; 2022 Jan; 566():16-25. PubMed ID: 34844082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Catenin signaling in hepatocellular carcinoma.
    Xu C; Xu Z; Zhang Y; Evert M; Calvisi DF; Chen X
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.
    Lu LC; Shao YY; Lee YH; Hsieh MS; Hsiao CH; Lin HH; Kao HF; Ma YY; Yen FC; Cheng AL; Hsu CH
    Oncology; 2014; 87(3):159-66. PubMed ID: 25012536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
    Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
    J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.